Román UG

Idioma: Español
Referencias bibliográficas: 25
Paginas: 187-192
Archivo PDF: 387.97 Kb.

RESUMEN

El presente trabajo revisa la farmacología básica y clínica del ácido zoledrónico, con base en la evidencia científica existente en la literatura. Este medicamento tradicionalmente ha sido utilizado para el manejo de la resorción ósea secundaria a varios tipos de cáncer. Y recientemente se suma al grupo de bifosfonatos utilizados en el manejo de la osteoporosis, con la particularidad de su administración intravenosa.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Anton, Karin et al. Zoledronic Acid and Secondary Prevention of Fractures. N Eng J Med. Nov 1, 2007. Tomo 357, No 18 p 1861.

2. Black, Dennis M. et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Eng J Med. May 3, 2007. Tomo 356, No 18, p 1809.

3. Borrás-Blasco, J. et al. Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid. Journal of Clinical Pharmacy and Therapeutics (2007) 32, 651-654.

4. Brown, Janet E. et al. Prolonged Efficacy of a Single Dose of the Biphosphonate Zoledronic Acid. Clin Cancer Res 2007; 13 (18) September 15, 2007.

5. Compston, Juliet. Treatments for Osteoporosis-Looking beyond the HORIZON. N Eng J Med. May 3, 2007. Tomo 356. No 18 p 1878.

6. Cheer, Susan M. et al. Zoledronic Acid. Drugs 2001; 61 (6): 799-805.

7. Deftos, L J. Treatment of Paget´s disease- Taming the Wild Osteoclast. N Eng J Med. Sep 1, 2005. Tomo 353, No. 8 p 872.

8. Dunford, James et al. Structure- Activity relacionships for inhibition of Farnesyl Diphosphate Synthase in vitro and Inhibition of Bone Resorption in vivo by Nitrogen-Containing Biphosphonates. The Journal of Pharmacology and Experimental Therapeutics. Vol 296, No 2 p 235-242.

9. Higano, Celestia. Annual Zoledronic Acid: Is Less More?. Journal of Clinical Oncology. Mar 9, 2007. Vol 25 No. 9.

10. Hof, Liesbeth. Aclasta® (ácido zoledrónico) Declaración sucinta (BSS). Departamento de registro farmacéutico, Novartis Pharmaceuticals. Distribuido 28 de setiembre del 2006.

11. Infante Cossío, Pedro et al. Biphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Med Oral Patol Oral Cir Bucal. 2008, Ene 1. 13(1) E: 52-E57.

12. Keating, William M. and Scott, Lesley. Zoledronic Acid: a Review of its use in the treatment of Paget´s Disease of Bone. Drugs 2007 67 (5).

13. Lambrinoudaki, Irene et al. Biphosphonates. Ann NY Acad Sci. 1092: 397-402. (2006).

14. Liel, Yair et al. Paget´s Disease and Biphosphonates / authors reply. N Eng J Med, Dec 15 2005, Tomo 353 No. 24 p 2616.

15. Lipton, Allan et al. Zoledronic Acid and Survival in Breast Cancer patients with Bone Metastases and Elevated markers of Osteoclast Activity. The Oncologist, Dec 12, 2007. 1035- 1043.

16. Lyles, Kenneth W. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Eng J Med, Noviembre 1 2007;357:1799-809.

17. Maricic, Michael. New and emerging treatments for osteoporosis. Curr Opin Rheumatol. 19; 364-369. 2007.

18. Mora, O. Cartas al Director. Farm Hosp 2007; 31: 315-324.

19. Reid, Ian R. et al. Intravenous Zoledronic Acid in postmenopausal women with low bone mineral density. N Eng J Med Feb 28, 2002. Tomo 346 No. 9 p 653 y ss.

20. Reginster, J Y. Oral and Intravenous Ibandronate in the Management of Postmenopausal Osteoporosis: A comprehensive review. Current Pharmaceutical Designs. 2005. 11, 3711-3728.

21. Reszka, Alfred. Nitrogen Containing Biphosphonate Mechanism of Action. Mini reviews in Medical Chemistry, 2004. 711-719.

22. Vieillard, Marie-Héleine, et al. Thirteen cases of jaw osteonecrosis in patients on biphosphonate therapy. Joint Bone Spina 75 (2008) 34-40.

23. Unknown autor. Once Yearly IV Biphosphonate for Osteoporosis. The Medical Letter: On Drugs and Therapeutics. Vo 49 Issue 1273. Nov 5 2007.

24. www.fda.gov

25. www.emea.europea.eu